A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis
Terminated · Phase 2 · NCT06859294
Conditions: Rheumatoid Arthritis
At a glance
- Research payments reported, 2025
- $12
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 35
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3541860 (drug)
- Dates
- Started 2025-03-19; completion 2026-06-05
- Results posted
- Not yet
The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD). Study participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period.
From ClinicalTrials.gov, last updated 2026-06-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $12 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Aqualane Clinical Research LLC $12
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.